AbbVie delivered adjusted earnings per share of $3.82 in the third quarter, beating Wall Street's consensus of $3.74. Net revenue totaled $17.40 billion, exceeding the $17.34 billion estimate.
The company raised full-year adjusted EPS guidance to $13.95-$13.99 from its prior range of $13.76-$13.96.
Skyrizi revenue reached $5.78 billion, beating the $5.74 billion estimate. Rinvoq generated $2.71 billion, slightly above the $2.70 billion consensus. These immunology assets are now core revenue drivers as Humira, once a blockbuster, declined to $683 million—a marginal beat of $679.3 million—as biosimilar competition erodes its installed base.
Imbruvica fell short, posting $522 million against a $527.3 million estimate, signaling continued headwinds in oncology.
